
Please try another search
For the three months ended 31 March 2022, Terns Pharmaceuticals Inc revenues was not reported. Net loss increased 3% to $13.8M. Higher net loss reflects Stock-based Compensation in SGA increase of 46% to $2M (expense), General and administrative - Balancing increase of 16% to $3.7M (expense), Stock-based Compensation in R&D increase of 60% to $770K (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 1 | 0 | 0 |
Gross Profit | ||||
Operating Income | -13.82 | -13.88 | -11.87 | -10.82 |
Net Income | -13.77 | -14.25 | -11.84 | -10.74 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 156.67 | 168.07 | 179.89 | 188.01 |
Total Liabilities | 7.95 | 7.77 | 7.73 | 6.67 |
Total Equity | 148.72 | 160.3 | 172.16 | 181.33 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -13.3 | -41.83 | -31.16 | -23.08 |
Cash From Investing Activities | 9.49 | -119.7 | -113.28 | -117.72 |
Cash From Financing Activities | 0 | 134.39 | 134.38 | 133.58 |
Net Change in Cash | -3.82 | -27.16 | -10.1 | -7.26 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review